Wall Street brokerages expect Agile Therapeutics Inc (NASDAQ:AGRX) to post earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Agile Therapeutics’ earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.16). Agile Therapeutics reported earnings per share of ($0.26) in the same quarter last year, which would suggest a positive year-over-year growth rate of 34.6%. The firm is expected to issue its next earnings report on Monday, November 5th.
On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.56). For the next year, analysts forecast that the company will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.94) to ($0.41). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Friday, August 3rd. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01.
A number of equities analysts have recently weighed in on the stock. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, August 3rd. Royal Bank of Canada cut their price objective on shares of Agile Therapeutics to $3.00 and set an “outperform” rating for the company in a research report on Monday, May 21st. Finally, HC Wainwright set a $4.00 price objective on shares of Agile Therapeutics and gave the company a “buy” rating in a research report on Monday, May 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Agile Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $6.25.
In other news, insider Life Sciences Maste Perceptive sold 298,628 shares of the business’s stock in a transaction that occurred on Thursday, July 26th. The shares were sold at an average price of $0.30, for a total value of $89,588.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.30% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its holdings in Agile Therapeutics by 76.3% in the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock valued at $392,000 after purchasing an additional 343,290 shares during the period. A.R.T. Advisors LLC grew its holdings in Agile Therapeutics by 82.3% in the first quarter. A.R.T. Advisors LLC now owns 66,426 shares of the specialty pharmaceutical company’s stock valued at $170,000 after purchasing an additional 29,995 shares during the period. Dimensional Fund Advisors LP grew its holdings in Agile Therapeutics by 62.8% in the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock valued at $373,000 after purchasing an additional 55,937 shares during the period. Franklin Resources Inc. grew its holdings in Agile Therapeutics by 17.0% in the first quarter. Franklin Resources Inc. now owns 3,355,200 shares of the specialty pharmaceutical company’s stock valued at $8,623,000 after purchasing an additional 487,400 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Agile Therapeutics by 113.1% in the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,654 shares during the period. Hedge funds and other institutional investors own 69.79% of the company’s stock.
Shares of NASDAQ:AGRX remained flat at $$0.25 during trading on Thursday. 224,373 shares of the stock were exchanged, compared to its average volume of 492,618. The firm has a market capitalization of $8.77 million, a price-to-earnings ratio of -0.28 and a beta of 1.48. Agile Therapeutics has a twelve month low of $0.23 and a twelve month high of $5.40.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Read More: Trading Strategy
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.